Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.52) per share which beat the analyst consensus estimate of $(1.61) by 5.59 percent. This is a 26.67 percent decrease over losses of $(1.20) per share from the same period last year.